November 9, 2021

Eprontia™ (topiramate) 25mg/mL oral solution has received U.S. FDA approval to treat seizures and prevent migraines in children and adults.

  • The new approval grants three indications to Eprontia:
    • Use as a monotherapy to treat partial-onset or primary generalized tonic-clonic seizures in patients at least two years of age;
    • Use as adjunctive therapy to treat partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox Gastaut syndrome in patients at least two years old; and
    • Use as a monotherapy for preventive treatment of migraines in patients who are at least 12 years old.
  • Eprontia is the first and only FDA-approved ready-to-use liquid formulation of topiramate, its active pharmaceutical ingredient.
  • Recommended dosing is determined by multiple factors, including the patient’s age and weight,
    the condition being treated, and the clinical response to treatment.
  • Azurity Pharmaceuticals, the manufacturer, has launched Eprontia at a wholesale acquisition cost (WAC) of $665 per 473mL bottle.
July 31, 2022

Brand Medications with Generic Alternatives Anticipated to be Approved in August

Read More
July 19, 2022

FDA Approves First Therapy for Repigmentation in Vitiligo

Read More
July 15, 2022

Zonisade Approved to Treat Seizures

Read More
July 14, 2022

Xalkori Granted New Indication to Treat Non-Cancerous Tumors

Read More